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ADP-ribosylation (ADPr) is a reversible posttransla-
tional modification involved in a range of cellular pro-
cesses. Here, we report system-wide identification of
serine ADPr in human cells upon oxidative stress.
High-resolution mass spectrometry and unrestricted
data processing confirm that serine residues are the
major target of ADPr in HeLa cells. Proteome-wide
analysis identifies 3,090 serine ADPr sites, with
97% of acceptor sites modulating more than 2-fold
upon oxidative stress, while treatment with the poly
(ADP-ribose) polymerase (PARP) inhibitor olaparib
abrogates this induction. Serine ADPr predominantly
targets nuclear proteins, while structural-predictive
analyses reveal that serine ADPr preferentially tar-
gets disordered protein regions. The identified
ADP-ribosylated serines significantly overlap with
known phosphorylated serines, and large-scale
phosphoproteomics analysis provides evidence for
site-specific crosstalk between serine ADPr and
phosphorylation. Collectively, we demonstrate that
serine ADPr is a widespread modification and a ma-
jor nuclear signaling response to oxidative stress,
with a regulatory scope comparable to other exten-
sive posttranslational modifications.INTRODUCTION
ADP-ribosylation is a posttranslational modification (PTM) in
which an ADP-ribose moiety is transferred from NAD+ to the
amino acid side chain of target proteins (Ueda and Hayaishi,
1985), thereby altering the function of the modified protein,
providing a regulatory mechanism for protein-protein interac-
tions, or regulating protein localization (Hottiger, 2015; Jungmi-
chel et al., 2013; Seman et al., 2004). The modification entails
either the addition of a single mono-ADP-ribose, referred to asCell Re
This is an open access article under the CC BY-Nmono-ADP-ribosylation (MAR), or the addition to an already pro-
tein-bound ADP-ribose to form poly-ADP-ribosylation (PAR)
(Schreiber et al., 2006). ADP-ribosylation (ADPr) is catalyzed by
a class of enzymes known as ADP-ribosyltransferases (ARTs),
which can be divided into twomajor subclasses, ARTCs (cholera
toxin-like, also known as ecto-ARTs) and ARTDs (diphtheria
toxin-like, formerly called PARPs [poly (ADP-ribose) polymer-
ases]), depending on their conserved structural features (Hot-
tiger et al., 2010). ARTDs/PARPs are known as crucial enzymes
in biological processes related to cancer development (Gibson
and Kraus, 2012; Schreiber et al., 2006), with PARP inhibitors
emerging as promising anticancer agents and commonly used
in the clinic for treatment of ovarian and breast cancer (Lord
and Ashworth, 2017; Pommier et al., 2016; Rouleau et al., 2010).
Within mammalian cells, ADPr can enzymatically be attached
to several amino acid residues, including Glu, Asp, Lys, Asn, His,
Arg, Cys, and Ser (Leung, 2017). Recently, western blot analyses
revealed that serine residues are amajor ADPr target during DNA
damage (Palazzo et al., 2018). Serine ADPr is catalyzed by
ARTD1/PARP1 and ARTD2/PARP2 and requires the co-factor
histone PARylation factor 1 (HPF1) to attach ADP-ribose groups
onto the side chain of serine residues (Bonfiglio et al., 2017).
Similar to most PTMs, serine ADPr is dynamic and can be enzy-
matically removed by the hydrolase ARH3 (Abplanalp et al.,
2017; Fontana et al., 2017). Despite representing amajor fraction
of total ADPr after DNA damage in mammalian cells (Palazzo
et al., 2018), identification of the proteins and individual serine
ADPr acceptor sites still remains challenging. Initial investiga-
tions aimed at mapping serine residues carrying ADPr yielded
79 and 224 serine acceptor sites, respectively (Bilan et al.,
2017; Bonfiglio et al., 2017). With hundreds of proteins globally
known to be targeted by ADPr (Vivelo et al., 2017), we reasoned
that the extent of serine ADPr is likely to be far greater than
currently reported. Thus, to gain further insight into the serine
ADP-ribosylome, we performed a system-wide analysis in
HeLa cells using an augmented proteomics Af1521 enrichment
strategy.
For confident mapping of the amino acid residues modified
with ADPr, all enriched peptideswere sequenced using high-res-
olution electron transfer dissociation (ETD) fragmentation (Coonports 24, 2493–2505, August 28, 2018 ª 2018 The Author(s). 2493
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Unbiased Localization of ADPr Acceptor Sites
(A) Overview of the experimental design. Briefly, quadruplicate (n = 4) cultures of HeLa cells were subjected to the indicated treatments, after which tryptic
digestion was performed, and subsequently ADPr peptides were enriched using the Af1521 macrodomain. All samples were analyzed by MS as single-shot
analyses using electron transfer dissociation (ETD) fragmentation, followed by unrestricted data processing.
(B) Average Pearson correlation of identified ADPr peptides (localization probability >0.90) from the three conditions. Error bars represent SD.
(C) Volcano plot analysis to visualize ADPr dynamics in response toH2O2 treatment. Blue dots indicate upregulated proteins, and red dots indicate downregulated
proteins.
(legend continued on next page)
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et al., 2005) on an Orbitrap Fusion Lumos mass spectrometer
(Senko et al., 2013), enabling proteome-wide mapping of ADPr
sites to great depth and facilitating a high degree of localization
confidence. Collectively, we identified 3,090 serine ADPr sites,
hereby significantly extending current knowledge of serine
ADPr while simultaneously providing insights into this emerging
modification. Exemplifying this, we find that serine ADPr signifi-
cantly overlaps with known phosphorylation sites. A systematic
kinase-substrate network analysis hinted that serine residues
usually modulated in phosphorylation by Aurora kinases were
primarily targeted by ADPr upon oxidative stress. Thus, we pro-
vide insight into widespread and site-specific crosstalk between
serine ADPr and serine phosphorylation. In conclusion, we pre-
sent a prominent resource on the serine-specific ADP-ribosy-
lome, demonstrating global and dominant increase in serine
ADPr upon oxidative stress and pinpointing a great number of
modified residues.
RESULTS
Unrestricted Analysis of Amino Acids Targeted by ADPr
With ADPr reported to target a wide range of amino acid residues
(Glu, Asp, Lys, Arg, His, Cys, and Ser) (Gupte et al., 2017), we
wanted to assess the capability of our proteomics strategy to
confidently localize ADPr. Therefore, we compared higher-
energy collisional dissociation (HCD) fragmentation with the
ETD fragmentation. In contrast to HCD, ETD fragmentation is
achieved by transferring electrons to the multiply charged cat-
ions, thereby introducing fragmentation randomly along the
peptide backbone in a sequence independent manner (Syka
et al., 2004). This makes ETD particularly useful for analysis of
labile modifications such as phosphorylation (Molina et al.,
2007) and ADPr (Zee and Garcia, 2010).
For comparison between HCD and ETD fragmentation, small-
scale quadruplicate HeLa cell cultures were treated with H2O2,
and ADPr peptides were purified using the Af1521 macrodomain
(Martello et al., 2016) and subsequently analyzed using either
HCD or ETD fragmentation. To assess the ability of HCD and
ETD for unbiased and confident localization of ADPr, an unre-
stricted search of the mass spectrometry (MS) data was per-
formed, by allowing the ADPr moiety to reside in silico on any
of the 20 naturally occurring amino acids.
Overall, we observed that the largest number of ADPr peptides
were identified and localized with ETD fragmentation in combi-
nation with detection of peptides in the Orbitrap mass analyzer
(Figure S1A). Compared to the Orbitrap mass analyzer, the
poor resolution of the ion trapmore frequently resulted in a failure
to faithfully identify and localize ADPr. Surprisingly, whereas
HCD analysis resulted in a considerably larger number of(D) Localization probability distribution of identified ADPr peptide-spectrum mat
ability that we used for filtering our data.
(E) Histogram depicting the distribution of identified acceptor amino acid residues
which we confidently localized ADPr in quadruplicate are indicated in blue, and o
green. Inset: regulation of serine ADPr upon H2O2 and PARP inhibition. Error bar
(F) Fully annotated representative ETD tandem mass spectrum of an ADP-ribosyl
(red) pinpointing the ADPr to reside on a serine residue.
See also Figure S1.MS/MS scans, only a very small fraction of these scans (<1%)
could be confidently localized when using a fully unrestricted
search (Figure S1B). Collectively, this demonstrated the analyt-
ical superiority of ETD fragmentation for confident localization
of ADPr.
To obtain an unbiased assessment of amino acids modified
with ADPr and assess the effect of oxidative stress on the distri-
bution of modified amino acids, we performed quadruplicate ex-
periments in HeLa cells either mock treated or exposed to H2O2
in the presence or absence of the PARP inhibitor olaparib (Fig-
ure 1A). In this experiment, ADPr peptides were enriched using
our established Af1521 enrichment approach (Martello et al.,
2016) and subsequently analyzed by single-shot MS. We ob-
tained a high degree of reproducibility between our experimental
replicates (Figures 1B and S1C), which facilitated reliable quan-
tification of the analyzed samples using label-free quantification
(LFQ) (Cox et al., 2014). In response to H2O2 treatment, we
observed a substantial increase in ADPr peptides, with the ma-
jority of ADPr events being upregulated more than 2-fold (Fig-
ure 1C). Conversely, the induction was entirely abrogated
when treating cells with the PARP inhibitor olaparib prior to
oxidative stress (Wahlberg et al., 2012) (Figure S1D).
Acquired MS/MS spectra were searched using our unre-
stricted approach, with assignment solely based upon high-res-
olution ETD data, thus unconditionally relying on the non-ergodic
fragmentation propensity entailed in the acquired ETD MS/MS
spectra for determination of ADPr acceptor sites (Zubarev
et al., 1998). From our unrestricted data processing, we obtained
confident localization of ADPr within modified peptides, with
1,297 ADPr sites identified and localized at a probability of
>90% (Figure 1D). 1,204 of the 1,297 (93%) ADPr sites confi-
dently localized to serine residues (Figure 1E).
Our finding substantiates initial observations that serines are
prominent targets of ADPr in human cells (Leidecker et al.,
2016; Palazzo et al., 2018) while providing quantitative and
site-specific insight into the cellular prevalence of the modifica-
tion during oxidative stress (Figure 1E). Upon oxidative stress,
predominantly serine ADPr sites were modulated, while treat-
ment of cells with PARP inhibitor (olaparib) abrogated their
stress-induced regulation (Figures 1E and S1E). Notably, our
ETD analysis demonstrated prodigious fragmentation spectra
of serine ADPr peptides, providing unambiguous localization of
the modified residue (Figure 1F). Having established a strategy
for studying serine ADPr, we next sought to investigate the
cellular extent of the modification in more detail.
Mapping the Serine ADP-Ribosylome
To gain comprehensive coverage of the serine ADP-ribosylome,
we combined our Af1521 enrichment strategy with previouslyches (PSMs). The dashed line visualizes the cutoff of >90% localization prob-
derived from unrestricted data processing of ETD data. Amino acid residues to
ther previously reported ADP-ribosylated amino acid residues are indicated in
s represent SD.
ated peptide. Full fragmentation is obtained, with both c-ions (blue) and z-ions
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Figure 2. Ultra-Deep Profiling of the Serine ADP-Ribosylome
(A) Overview of the experimental design for quantitative and deep profiling of the ADP-ribosylome. The overall strategy was the same as Figure 1A, with the
addition of on-StageTip high-pH fractionation of the enriched ADPr peptides (gray arrows). n = 4 cell culture replicates.
(B) Unsupervised hierarchical clustering analysis of Z-scored log2-transformed intensities of ADPr sites. Blue coloring indicates relative presence in a sample as
compared to others.
(C) Venn diagram visualizing overlap between serine ADPr sites identified in our study compared to other ADPr proteomics studies (drawn to scale).
(legend continued on next page)
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described high-pH (HpH) fractionation of modified peptides
(Hendriks et al., 2017; Larsen et al., 2016) (Figure 2A). Although
such pre-fractionation increases the overall requirements for
MS acquisition time, pre-fractionation greatly improves
sequencing depth of the analyzed samples (Bekker-Jensen
et al., 2017). Because unrestricted analysis comes with compu-
tational limitations, we streamlined data processing by perform-
ing a semi-restricted search, allowing ADPr to reside on all amino
acid residues that we detected to be ADP-ribosylated in quadru-
plicate in our unrestricted search (Cys, His, Arg, Ser, Thr, and
Tyr), along with previously reported amino acid residues (Glu,
Asp, and Lys).
Collectively, we observed a high degree of reproducibility (Fig-
ure S2A) and consistent regulation of ADPr sites in response to
oxidative stress (Figure 2B). In total, we identified 3,090 serine
ADPr sites with a localization probability of >90% (Table S1),
hereby greatly expanding current knowledge on this emerging
modification (Figure 2C) and underscoring that serine ADPr en-
tails a broad cellular distribution. Identified serine ADPr sites
mapped to 1,283 proteins (Table S2). We determined the effi-
ciency of our purification strategy and observed a global peptide
purity of 58%, with a purity of up to 95%–99% in the four most
hydrophilic fractions analyzed (Table S1).
Although we mainly detected serine ADPr in response to H2O2
treatment, 358 ADPr sites were detected under control condi-
tions and 339 ADPr sites when subjecting cells to oxidative
stress in the presence of olaparib (Table S1). Thus, baseline
ADPr events do occur but appear low abundant and may be
technically more challenging to detect. Nonetheless, we de-
tected >300 baseline ADPr sites, without resorting to poly
(ADP-ribose) glycohydrolase (PARG) knockdown in cells to
boost the numbers. Overall, ADPr on non-serine residues ap-
peared more frequently among H2O2-unregulated ADPr sites
(Table S1). We evaluated the subset of proteins exclusively
modified by ADPr on non-serine residues as compared to pro-
teins modified on at least one serine residue (Figure S2B).
Intriguingly, proteins modified by ADPr on non-serine residues
appeared to be more prominently localized in the cytoplasm,
further solidifying that serine ADPr is a predominant nuclear
modification.
To evaluate our depth of sequencing, we compared the iden-
tified ADP-ribosylome to the HeLa proteome (Bekker-Jensen
et al., 2017) and other abundant PTMs, such as phosphorylation
and ubiquitylation (Figure 2D; Table S3). While the deep prote-
ome study and global knowledge on phosphorylation surpassed(D) Visualization of depth of sequencing, by comparison of average protein expre
based absolute quantification (IBAQ) copy numbers of proteins were derived fro
studies indicate ADPr proteomics studies. For ubiquitin and phosphorylation, on
(PhosphoSitePlus) (Hornbeck et al., 2012). Total numbers of proteins identified a
ADPr target proteins identified in this study and other datasets, with blue or red as
Determined by two-tailed Fisher’s exact testing (*p < 0.05, **p < 0.001; x, not sig
(E) Gene Ontology (GO) term enrichment analysis of ADPr target proteins, as com
compartment; MF, molecular function.
(F) Pie-chart overview of the subcellular localization of serine ADPr target proteins
(GOCC).
(G) Distribution of serine ADPr sites per protein.
(H) Distribution of the fractional (relative to total) ADPr within the auto-modificatio
See also Figure S2 and Tables S1, S2, S3, and S4.our study in depth of sequencing, we found that our serine ADPr
analysis was on par with global knowledge of ubiquitylation
(Hornbeck et al., 2012) (Figure 2D), with serine ADPr systemically
occurring on less abundant proteins. When comparing our study
to other recent ADPr studies (Bilan et al., 2017; Jungmichel et al.,
2013; Martello et al., 2016; Zhang et al., 2013), we achieved a
comparable or improved sequencing depth while detecting a
considerably larger number of ADPr sites and proteins (Table
S3). Overall, this emphasizes that our analysis was not biased to-
ward abundant proteins.
Gene Ontology (GO) analysis showed a strong enrichment of
biological processes associated with nuclear ARTD/PARP activ-
ities (Figure 2E; Table S4). Over 90% of identified ADPr target
proteins were annotated as nuclear localized (Figure 2F), which
supports previous reports that PARP1 and PARP2 are respon-
sible for the observed increase in serine ADPr (Bonfiglio et al.,
2017). This is further supported by our observation of PARP-
inhibitor-dependent regulation of identified serine ADPr sites
(Figure 1E). Concomitantly, PARP1 and PARP2 were themselves
identified as targets of serine ADPr (Table S1), most likely
induced via auto-modification (Altmeyer et al., 2009; Kim et al.,
2004). When assessing the distribution of ADPr sites, we found
that 51% of identified proteins harbor only one serine acceptor
site, with 8% of identified proteins containing >5 modification
sites (Figure 2G). Hence, the distribution of serine ADPr is rela-
tively similar to other widespread modifications such as phos-
phorylation (Huttlin et al., 2010), arginine methylation (Larsen
et al., 2016), and ubiquitylation (Kim et al., 2011).
Overall, we found PARP1 to be themost abundant ADPr target
protein despite PARP1 not harboring the largest number of
modification sites (Table 1). Next, we decided to investigate
the relative contribution of individual ADPr sites as compared
to the total ADPr of target proteins (Tables 1 and S1). For
example, this fractional analysis demonstrated that in vivo
>99% of ADPr on PARP1 resided within the auto-modification
domain (Figure 2H), while serine ADPrwithin the DNA-binding re-
gion on S104, S140, and S204 constituted <1% of total ADPr on
PARP1 (Table S1). Thus, our fractional analysis of ADPr events
across all proteins provides another valuable dimension of bio-
logical insight.
Sequence Properties of Serine ADPr Sites
Previous studies reported that serine ADPr sites are often pre-
ceded by basic residues (Abplanalp et al., 2017; Leidecker
et al., 2016). As these studies identified a limited number ofssion levels identified across different subsets of data, as indicated. Intensity-
m a recent deep proteome study (Bekker-Jensen et al., 2017). Blue-colored
ly target proteins identified in three or more proteomics studies were included
re displayed above the bars. Asterisks denote significant differences between
terisks indicating whether our study achieved more or less depth, respectively.
nificant [NS]).
pared to the human proteome (Table S4). BP, biological process; CC, cellular
, with localization annotations derived fromGene Ontology Cellular Component
n domain of PARP1.
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Table 1. Fractional Modification Analysis of the ADP-Ribosylome
Protein ADPr # # S
Primary
ADPr Fraction
Secondary
ADPr Fraction
Tertiary
ADPr Fraction Biological Process
PARP1 1.4E+12 14 10 S-499 66.8% S-507 21.3% S-519 9.4% DNA repair
HIST1H2BC 8.1E+11 14 7 S-7 94.0% S-15 5.4% K-13 0.3% nucleosome
HIST1H3A 6.1E+11 7 3 S-11 86.3% S-29 11.1% K-10 2.1% nucleosome
HIST1H2BD 2.8E+11 6 2 S-7 84.5% S-15 14.6% K-13 0.4% nucleosome
HIST2H2BF 2.7E+11 5 2 S-7 84.0% S-15 15.2% K-13 0.4% nucleosome
HIST1H2BN 2.4E+11 5 2 S-7 81.9% S-15 17.3% K-13 0.4% nucleosome
HIST1H1D 2.3E+11 12 10 S-205 74.2% S-151 22.0% S-56 1.9% nucleosome
HMGA1 2.0E+11 3 3 S-8 60.8% S-9 39.2% S-44 0.0% transcription
HNRNPU 1.8E+11 8 6 S-695 85.1% S-187 14.7% S-690 0.1% mRNA processing
HIST1H4A 1.7E+11 2 1 S-2 67.2% R-4 32.8% – – nucleosome
HIST1H2BL 1.7E+11 5 2 S-7 74.0% S-15 24.7% K-13 0.6% nucleosome
HIST3H2BB 1.7E+11 7 2 S-7 73.9% S-15 24.8% K-13 0.6% nucleosome
RFC1 1.6E+11 39 34 S-302 31.2% S-1126 22.1% S-533 8.2% DNA replication
DIMT1 1.1E+11 2 2 S-6 58.6% S-24 41.4% – – rRNA processing
NPM1 1.1E+11 10 9 S-195 39.4% S-139 21.4% S-207 16.5% cell cycle
HIST1H1E 8.0E+10 12 8 S-150 91.2% K-149 5.9% S-102 1.0% nucleosome
HIST3H3 7.9E+10 1 1 S-29 100.0% – – – – nucleosome
SSRP1 6.9E+10 16 11 S-531 56.5% S-657 11.2% R-532 10.6% DNA repair
FEN1 6.8E+10 10 9 S-363 80.9% S-101 12.0% S-94 3.7% DNA repair
NUCKS1 5.9E+10 4 4 S-195 43.3% S-39 31.1% S-160 22.2% DNA repair
DEK 5.7E+10 6 6 S-211 76.7% S-210 18.3% S-279 4.6% DNA repair
TOP2A 5.7E+10 9 9 S-1449 43.5% S-1452 30.9% S-1423 17.7% cell cycle
BUD23 4.7E+10 6 3 S-248 60.6% R-249 38.0% S-240 1.1% transcription
HIST1H1C 4.3E+10 5 3 S-150 84.1% S-188 14.0% K-152 0.9% nucleosome
LIG3 4.1E+10 11 9 S-227 60.0% S-912 27.5% S-876 5.1% DNA repair
HMGB2 4.1E+10 4 2 S-168 94.6% K-173 2.8% S-181 2.2% transcription
NUSAP1 3.9E+10 22 19 S-305 36.2% H-307 14.6% S-311 14.4% cell cycle
HIST1H2BM 3.8E+10 3 2 S-7 99.1% K-13 0.9% S-15 0.0% nucleosome
CCDC86 3.7E+10 11 8 S-242 40.9% R-244 26.7% S-255 26.5% host-virus interaction
HMGN2 3.6E+10 2 2 S-29 99.6% S-25 0.4% – – immune response
CHD1L 3.4E+10 11 10 H-784 37.6% S-780 19.8% S-785 14.0% DNA repair
RBMX 3.0E+10 16 11 S-157 27.0% S-336 24.4% S-337 16.5% mRNA processing
KHDRBS1 2.9E+10 11 8 S-18 65.4% S-14 14.8% R-17 7.8% cell cycle
SUPT16H 2.8E+10 12 10 S-1031 40.1% S-1038 18.8% S-1039 15.4% DNA repair
NOLC1 2.8E+10 12 11 S-303 52.7% S-669 30.0% S-580 13.4% cell cycle
LMNA 2.7E+10 9 8 S-12 89.0% S-398 4.1% S-628 3.1% cell cycle
MKI67 2.3E+10 51 50 S-621 35.7% S-380 11.9% S-875 10.1% cell cycle
TMA7 2.3E+10 4 2 S-61 95.0% S-2 4.9% T-55 0.1% unknown
DDX21 2.1E+10 9 8 S-751 29.5% S-759 28.9% S-731 19.9% rRNA processing
BAZ1B 2.0E+10 14 10 R-455 42.7% S-417 29.6% S-347 9.9% DNA repair
HMGN1 2.0E+10 4 4 S-7 67.2% S-25 30.0% S-8 2.0% DNA repair
GTPBP4 1.9E+10 4 4 S-623 48.0% S-578 46.4% S-567 3.2% cell cycle
PPHLN1 1.9E+10 9 6 R-174 39.1% S-110 31.6% S-172 14.3% transcription
SUB1 1.8E+10 5 4 S-51 46.8% S-46 30.5% S-50 19.9% transcription
NAT10 1.8E+10 2 2 S-990 100.0% S-984 0.0% – – rRNA processing
HIST1H1A 1.7E+10 3 3 S-149 93.4% S-124 4.6% S-165 2.0% nucleosome
EXOSC10 1.6E+10 9 9 S-874 42.6% S-866 19.7% S-868 13.6% rRNA processing
(Continued on next page)
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Table 1. Continued
Protein ADPr # # S
Primary
ADPr Fraction
Secondary
ADPr Fraction
Tertiary
ADPr Fraction Biological Process
ZNF512B 1.5E+10 8 6 S-18 63.5% S-887 16.4% S-263 14.2% transcription
GPATCH11 1.4E+10 4 4 S-84 49.4% S-108 44.3% S-91 6.3% cell cycle
MITD1 1.4E+10 1 1 S-4 100.0% – – – – cell cycle
An overview of the top 50 most abundantly modified ADPr target proteins. The list highlights the top three most abundant ADPr sites (Table S2), visu-
alizing the predominant presence of serine ADPr. ADPr, total summed site intensity; #, total number of ADPr sites; #S, number of serine ADPr sites;
fraction, relative contribution of this ADPr site to the total ADPr modification of the protein; biological process, Gene Ontology Biological Process.serine ADPr sites, we decided to investigate ADPr-proximal
sequence context on a wider scale (Figure 3A). We observed a
strong preference for ADPr to be targeted to the lysine-serine
(KS) motif, as previously described. We also observed the
prevalence of a serine-glycine (SG) and, to a lesser extent, a
serine-glycine-glycine (SGG) motif. Intriguingly, such sequence
motifs are reminiscent of the arginine-glycine (RG) and
arginine-glycine-glycine (RGG) motifs commonly targeted by
arginine methylation (Thandapani et al., 2013), which our lab
has previously shown to relate to the abundance of the targeted
proteins (Larsen et al., 2016). Hence, we wondered if any of the
observed serine ADPr motifs might reflect a similar protein abun-
dance bias.
To investigate this, we selected subsets of ADPr target pro-
teins harboring at least 3 modification sites, with the majority
of their fractional intensity residing in either KS, or any SGG mo-
tifs, and assessed the known cellular expression levels of these
proteins. We observed that proteins with a majority of ADPr
residing in any SGG motifs were predominantly highly abundant
proteins, suggesting the influence of protein abundance bias
(Figure 3B). Intriguingly, ADPr target proteins predominantly
modified on KS motifs displayed the opposite trend and thus
demonstrated an anti-abundance bias. This suggests that KS
motifs preferentially exist in low-abundant proteins in order to
facilitate sufficient levels of ADPr in response to oxidative stress.
To further characterize serine ADPr, we performed structural-
predictive analysis on all proteins modified by ADPr. This anal-
ysis determined whether serine residues in these proteins
resided in disordered or globular regions and whether they
were solvent exposed or buried. Overall, 59% of serine residues
resided in disordered regions, whereas 75% of ADP-ribosylated
serine residues resided in disordered regions (Figure 3C). The
propensity of serine ADPr to target disordered regions is similar
to other modifications involved in nuclear signaling, including
phosphorylation (Figure 3C) (Iakoucheva et al., 2004). Hence,
the shared preference for disordered regions supports previous
findings where phosphorylation was observed in close proximity
of ADPr sites (Gibson et al., 2016).
Site-Specific Overlap of Serine ADPr and
Phosphorylation
ADPr and phosphorylation are known to functionally interact
(e.g., in the DNA damage response; Polo and Jackson, 2011),
but little is currently known about the site-specific crosstalk be-
tween the two modifications (Hunter, 2007). To assess this pos-
sibility, we first compared all identified serine ADPr sites to allphosphorylation sites known to reside within ADPr target pro-
teins (Table S4), with the phosphorylation sites derived from
PhosphoSitePlus and identified in at least 3 MS screens (Horn-
beck et al., 2012). Subsequently, we performed a large-scale
kinase prediction on all serines co-targeted by ADPr and
phosphorylation using the kinase-substrate enrichment applica-
tion (KSEA) (Hornbeck et al., 2012; Linding et al., 2007). As a
statistical background, we used known kinase motifs for all
serine phosphorylation sites entailed in the comparison. From
this analysis (Figure 3D), we found a strong enrichment for
Aurora kinases A and B (AURKA and AURKB) to modulate
ADPr-phospho co-targeted serines. Interestingly, AURKA and
AURKB strongly associate with PARP1 activity (Monaco et al.,
2005), and AURKA overexpression has been shown to result in
sensitivity to the PARP inhibitor olaparib (Sourisseau et al.,
2010).
To investigate this interplay in more detail, we performed
quantitative phosphoproteomics analysis in HeLa cells with the
same experimental conditions as used for establishing the serine
ADP-ribosylome (Figure 1A). From this, we identified >27,000
class 1 phosphorylation sites (Table S5), with a high degree of
reproducibility between replicates (Figures S3A and S3B). In to-
tal, 20,000 sites could be quantified in quadruplicate, and
1,818 and 1,266 phospho sites were significantly upregulated
anddownregulateduponH2O2 treatment, respectively (Figure4A;
Table S5). Pretreatment of cells with PARP inhibitor did not
notably modulate the phosphoproteome in response to 10 min
H2O2 treatment (Figure S3C). Nonetheless, we observed a wide
range of differentially regulated cellular processes for phospho-
proteins that were dynamically modified in response to H2O2
treatment (Figure 4B), with subtle variations in these affected
processes when investigating proteins containing either downre-
gulated or upregulated phospho sites (Figures S3D and S3E).
Interestingly, we found 483 serine ADPr sites overlapping with
phosphorylation sites detected in our phosphoproteomics anal-
ysis (Figure 4C; Table S4), which represented a significantly
higher degree of overlap compared to randomly expected.
Thus, ADPr and phosphorylation preferentially target the same
serine residues on a proteome-wide scale, with the high degree
of overlap further recapitulated when comparing our serine
ADP-ribosylome to literature data. Notably, the proportion of
the overlap is similar to the site-specific overlap between the
cross-regulatory modifications lysine acetylation and ubiquityla-
tion (Choudhary et al., 2014).
Overlap between serine ADPr and phosphorylation signifi-
cantly increased when only considering serine residues locatedCell Reports 24, 2493–2505, August 28, 2018 2499
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Figure 3. Site-Specific Properties of Serine ADPr
(A) IceLogo representation of the sequence context surrounding identified serine ADPr sites, using all serines in ADPr target proteins as a reference. Amino acids
portrayed above the line are enriched, whereas amino acids below the line are depleted. Amino acid height corresponds to SD change. All changes were sig-
nificant by two-tailed Student’s t test with p < 0.01.
(B) ADPr intensity compared to protein abundance. KS and SGG indicate enriched ADPr in the corresponding motifs (+) or otherwise depleted modification ().
‘‘All’’ denotes all ADPr target proteins. The dashed line represents the expected protein abundance bias.
(C) Schematic overview of structural properties of subsets of serines in human proteins targeted by ADPr as compared to structural properties of all other serines
within the same proteins (Table S4). A relative presence of 100% is indicative of no change as compared to the background. Phosphorylation (Phos) sites were
derived from PhosphoSitePlus and only considered if detected in 3 or more proteomics studies. ‘‘Both’’ corresponds to serine residues detected as ADP-
ribosylated in this study and phosphorylated in PhosphoSitePlus (PSP) data. All displayed values were significant by Fisher exact testing with a Benjamini-
Hochberg multiple-hypotheses corrected p < 0.02.
(D) Kinase enrichment analysis visualizing kinases enriched for serine residues co-targeted by ADPr and phosphorylation compared to all phosphorylated serine
residues in ADPr target proteins (Table S4). Kinase predictionswere extracted using the kinase-substrate enrichment application (KSEA), with information derived
from NetworKIN (Net) and PSP (Hornbeck et al., 2012). All displayed values were significant by Fisher exact testing with a Benjamini-Hochberg multiple-
hypotheses corrected p < 0.02.
See also Table S4.outside of the canonical phosphorylation serine-proline (SP)
motif (Figure 4C). Similarly, when considering ADPr-phospho
crosstalk outside of the ADPr-preferred KS motifs, we again
observed a significantly higher degree of overlap. To further
this, we evaluated the relative preferences of ADPr and phos-
phorylation for targeting KSmotifs (Figure 4D) and found a strong
preference for ADPr to target thesemotifs, contrary to phosphor-
ylation. When considering SP motifs (Figure 4E), we confirmed
the preference of phosphorylation to be targeted to these motifs
but moreover a highly significant propensity for ADPr to entirely
avert targeting SP motifs. SP-driven phosphorylation sites typi-
cally constitute the majority of identified phosphorylation sites
in standard proteomics experiments (Huttlin et al., 2010), and
thus the aversion of serine ADPr to SP motifs seemed quite2500 Cell Reports 24, 2493–2505, August 28, 2018remarkable. With cyclin-dependent kinases (CDKs) typically
responsible for catalyzing phosphorylation of SP motifs
(Amanchy et al., 2007), site-specific regulation of ADPr may
functionally not relate to biological processes involving CDK ac-
tivity. No kinase has been reported to catalyze phosphorylation
in KS motifs, and although serine ADPr preferentially localized
to KS motifs (Figures 3A and 4D), the overlapping modification
sites were more frequently observed outside of KS motifs
(Figure 4C).
To assess the effect of ADPr on phosphorylation and the po-
tential involvement of kinases in a more direct manner, we
analyzed the propensity of ADPr, phosphorylation, or both to
modify serines residing within all known kinase motifs in the
co-targeted proteins (Figure 4F; Tables S4 and S5).We observed
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Figure 4. Co-targeting of ADPr and Phospho to Serines and Kinase Motifs
(A) Volcano plot analysis to visualize phosphorylation dynamics in response to H2O2 treatment. Red, silver, and blue dots indicate downregulated, non-regulated,
and upregulated phospho sites, respectively. n = 4 cell culture replicates, q-value < 0.05 for significance; permutation-based false discovery rate (FDR) calculated
at an s0 of 0.1.
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several kinase motifs to be strongly enriched for co-targeting by
both phosphorylation and serine ADPr, with RAC-alpha serine/
threonine-protein kinase (AKT1), AURKA and AURKB, and pro-
tein kinase C (PRKCA and PRKACA) being among the top hits.
Likewise, we noted a PARP-dependent effect on the directional
regulation of phosphorylation sites preferentially modulated by
the AKT1, AURKB, PRKCA, and PRKACA kinases (Figure S4A).
Interestingly, among the identified serine ADPr sites, we
observed a stronger enrichment for modification of AURKA/B
kinase motifs, as compared to the corresponding phos-
phorylation sites (Figure 4F). Using immunoblot analysis, we
confirmed that the activity of AURKA/B is temporally regulated
in a PARP-dependent manner (Figure S4B). Similarly, the phos-
phorylation status of known AURKB substrates histone H3
(Ser10) and transforming acidic coiled-coil-containing protein 3
(TACC3, Ser558) were PARP dependent (Figures S4D and
S4E). Considering that AURKA, AURKB, and histone H3 Ser10
were ADP ribosylated in our dataset, this supports the regulatory
interplay between the modifications.
In spite of overlapping sites between serine ADPr and phos-
phorylation infrequently occurring in SP motifs, the proteins
harboring co-targeted modification sites were observed to be
functionally interconnected and moreover globally relate to the
cell cycle (Figure 4G). This suggested that while phosphorylation
sites catalyzed by CDKs might not participate in direct crosstalk
with serine ADPr, the site-specific crosstalk between the modifi-
cations could still play a functional role in cell cycle regulation
(Adolph, 1985).
Collectively, our data suggest alignment in the directionality of
ADPr and phosphorylation in the early response to oxidative
damage and that shared targeting of same serine residues by
PARP enzymes and the Aurora kinases may entail a hitherto un-
characterized layer in cellular signaling.
DISCUSSION
Here, we describe proteome-wide identification of serine ADPr
sites in human cells and provide quantitative insights into serine
ADPr dynamics upon oxidative stress. In total, we report
identification of 3,090 serine ADPr sites, providing an in-depth(B) GO term enrichment analysis of dynamically phosphorylated proteins upon H
processes; CC, cellular compartments, MF, molecular functions. All displayed
multiple-hypotheses corrected p < 0.02.
(C) Relative overlap between subsets of serine residuesmodified by ADPr and pho
to the background. All displayed values were significant by Fisher exact testing wi
sites derived from PSP, detected in 3 or more proteomics studies; Map., phosph
(D) Propensity of serines targeted by ADPr, phosphorylation, or both, to reside in K
in 3 or more proteomics studies; Map., phospho sites mapped in this study.
(E) As in (D), but for SP motifs.
(F) Kinase enrichment analysis based on our experimental data, visualizing the
modified by phosphorylation, ADPr, or both PTMs. As a background, all serine r
were extracted from PSP and aligned to these serines (754 kinase motifs and 89
testing with a Benjamini Hochberg multiple hypotheses corrected p < 0.05, unle
(G) Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) networ
residues co-targeted by ADPr and phosphorylation based on our experimental da
proteins were omitted from the network. Nodes corresponding to proteins were a
overlap, number of co-targeted serine residues; AURK motif, at least one co-targ
See also Figures S3 and S4 and Tables S4 and S5.
2502 Cell Reports 24, 2493–2505, August 28, 2018compendium of the human serine ADP-ribosylome. The proteins
targeted by serine ADPr prominently localize to the nucleus,
which together with our quantitative analyses demonstrate that
serine ADPr is a major nuclear responder to oxidative stress.
Many regulatory systems exist in human cells, and serine ADPr
appears to be intricately involved, with themodification targeting
ubiquitin ligases, protein kinases, methyltransferases, RNA-in-
teracting proteins, and numerous other enzymes involved in
cellular signaling events. Our data furthermore highlight that
the ADPr stimulus is distributed to transcriptional regulators
and co-regulators during oxidative stress.
Notably, the distribution of ADP-ribosylated amino acids
observed in our dataset differs from previous reports des-
cribing glutamic and aspartic acid as targets of ADPr (Gibson
et al., 2016; Zhang et al., 2013; Zhen et al., 2017). These
studies utilized an analytical strategy directed toward ADPr
on acidic residues only and were thus incapable of identifying
serine ADPr. Although our strategy does not suffer from this
limitation (Figure 1; Data S1), our dataset does not entail a
similar extent of ADPr of glutamic and aspartic acids. Consid-
ering that the Af1521 domain does not exhibit any hydrolase
activity during our experimental conditions (Jungmichel et al.,
2013; Martello et al., 2016), our data suggest that serine
ADPr is more abundantly present in human cells than ADPr of
glutamic and aspartic acids. Furthering this, most proteins
modified on non-serine residues in our dataset were also modi-
fied on one or more serine residues (Table S2), which could
explain why targeted strategies are required for the investiga-
tion of ADPr on acidic residues (Zhang et al., 2013). The cellular
abundance difference is further supported by a recent observa-
tion using complementary approaches, where serine ADPr was
reported to constitute a major target during DNA damage, and
where co-factor HPF1 was shown to direct the catalytic amino
acid preference of PARP enzymes to serine residues (Bonfiglio
et al., 2017).
Whether the extent of the serine ADP-ribosylome reported in
the current study primarily depends upon HPF1 (Gibbs-Seymour
et al., 2016) remains to be determined. However, treating cells
with olaparib abrogated the cellular induction of serine ADPr in
response to H2O2, suggesting that serine ADPr represents the2O2 treatment as compared to the human proteome (Table S4). BP, biological
values were significant by Fisher exact testing with a Benjamini-Hochberg
sphorylation. A relative overlap of 100% is indicative of no change as compared
th a Benjamini Hochberg multiple hypotheses corrected p < 0.02. Lit., phospho
o sites derived from our phosphoproteomics experiments.
S motifs. Lit., phospho sites derived from PSP and only considered if detected
propensity of serine residues to reside in known kinase motifs when they are
esidues in ADPr target proteins were considered, and all known kinase motifs
,012 serines; Table S4). All displayed values were significant by Fisher exact
ss indicated with an ‘‘x.’’ Statistical information is further detailed in Table S4.
k visualizing functional interactions between proteins with at least two serine
ta. Default STRING clustering confidence was used (p > 0.4), and disconnected
nnotated with visual properties, as highlighted in the figure legend. ADPr-phos
eted serine residue is modulated by AURKA or AURKB.
primary biological mode of action. Olaparib is used in the clinic
as a therapeutic agent for treatment of ovarian and breast
cancer, and our dataset detailing the molecular targets of the
inhibitor may consequently aid in a better understanding of the
molecular mechanism related to clinical resistance of PARP in-
hibitor treatment.
Notably, the extent of serine ADPr sites reported herein differs
from previous observations (Martello et al., 2016), as previous
mass spectrometric and bioinformatics approaches were not
configured to facilitate detection of the recently reported serine
ADPr. Our current strategy does not suffer from such limitations
and facilitates purification and detection of any amino acid
residue being modified by ADPr. However, a limitation of our
approach is that it cannot address whether identified ADPr sites
were initially MAR or PAR, as this information is lost during PARG
treatment. However, considering serine ADPr is primarily cata-
lyzed by PARP1, we assume that the majority of identified sites
represent PARylation.
To demonstrate the potential of our resource to derive
biological insights that are not easily obtainable through low-
throughput strategies, we determined the fractional contribution
of all serine ADPr sites to the total ADPr abundance of individual
target proteins. In turn, this provides valuable quantitative in-
sights into the site-specific levels of ADPr and constitutes a valu-
able resource for generation of separation-of-function mutations
in proteins targeted by serine ADPr.
Full-scale structural-predictive analysis demonstrated that
serine ADPr preferentially targeted disordered regions in target
proteins. Thus, the structural preference of the PARP1/2
enzymes is similar to those catalyzing other widespread modifi-
cations, including phosphorylation kinases and the SUMO
enzymatic machinery. As cancer-associated and signaling pro-
teins tend to have a higher proportion of residues in disordered
regions compared to other proteins (Iakoucheva et al., 2002),
the observed preference of serine ADPr could indicate a more
prevalent involvement in cellular signaling than currently
anticipated.
Our data reveal evidence of a shared targeting preference be-
tween serine ADPr and phosphorylation, with identified serine
ADPr sites significantly overlapping with serine phosphorylation
sites, suggesting site-specific regulatory interplay between the
two modifications. Such interplay has previously been observed
on histones, where the overall phosphorylation status of histones
was reduced upon ADPr (Tanigawa et al., 1983). Intriguingly, we
observed several ADPr sites to overlapwith known histone phos-
phorylation sites (Table S1), whichmay account for the observed
regulatory phenotype. However, it remains to be investigated
whether the observed overlap codifies a negative crosstalk,
where one modification outcompetes the other, or a positive
crosstalk, where one modification temporarily precedes the
other (Hunter, 2007).
Phosphoproteomics and kinase-prediction analyses re-
vealed a strong propensity for ADPr to target serine residues
that are modulated in phosphorylation status through the ac-
tion of AURKA/B. Moreover, we find both AURKA/B to be
modified by serine ADPr, and ADPr was previously shown to
affect AURKB kinase activity (Monaco et al., 2005). With over-
expression of AURKA reported to lead to an enhanced sensi-tivity to PARP inhibitors (Sourisseau et al., 2010), our observa-
tions provide insight into an emerging and site-specific
interplay between serine ADPr catalyzed by PARP and phos-
phorylation catalyzed by AURKA/B. For example, among
proteins targeted by modifications on same serine residues,
we noticed that breast cancer type 1 susceptibility protein
(BRCA1) is modified with ADPr on serine 308 (Table S1). The
same serine residue constitutes a known phosphorylation
target of AURKA, which upon phosphorylation of BRCA1
leads to increased microtubule assembly rates and chromo-
some missegregation (Ertych et al., 2016). Because BRCA-
defective tumors are particularly sensitive to PARP inhibitors
following the concept of synthetic lethality and loss of
BRCA1 or BRCA2 function results in sensitivity to the inhibi-
tion of PARP (Helleday, 2011), site-specific regulation of phos-
phorylation and serine ADPr on BRCA1 could constitute a
regulatory layer within the synthetic lethality of PARP inhibi-
tors (Helleday, 2011). Along these lines, the PARP inhibitor
olaparib has been described as a strong inducer of chromo-
some missegregation in human cells (Colicchia et al., 2017;
Lee et al., 2016). While this underscores the complex interplay
between various modifications and the proteins they target, it
also displays the necessity for systems-wide proteomics
analyses to gain valuable biological insight into the regulatory
scope of currently obscure modifications. Collectively, the
presented human serine ADP-ribosylome provides a missing
piece in the global and integrative view of cellular physiology
and comprises a vast biological resource.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
HeLa cells (CCL-2, female) were acquired from the American Type Culture Collection, and cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal bovine serum and penicillin/streptomycin (100 U/mL; GIBCO) at 37C and 5%
CO2. Cells were not routinely authenticated. Cells were routinely tested for mycoplasma contamination.
Bacteria
BL21(DE3) Competent E. coli were acquired from New England BioLabs. Details regarding culture conditions are outlined in the
method details.
METHOD DETAILS
Cell treatment
In order to study ADP-ribosylation in the context of the DNA damage response, 75 million HeLa cells were cultured per single-shot
mass spectrometry (MS) replicate, and 150 million HeLa cells were prepared for each pre-fractionated MS replicate. HeLa cells
were either left untreated (control) or treatedwith 1mMH2O2 (Sigma Aldrich) for 10min in PBS at 37
Cwith or without prior incubation
with the PARP inhibitor Olaparib (10 mM; Selleckchem) for 1 h. Quadruplicate cultures were prepared for all biological conditions. Fore1 Cell Reports 24, 2493–2505.e1–e4, August 28, 2018
western blot (WB) analysis, cells were left untreated or treated with 1 mM H2O2 for the indicated time points, in medium, and with or
without prior incubation with Olaparib for a total of 3 h. All western blot analyses were performed in duplicate.
Cell lysis and sample preparation
To achieve a high recovery of proteins and avoid loss of biologically labile PTMs, we used a procedure based on lysis with the highly
chaotropic agent guanidine-HCl. Cells were washed twice with ice-cold PBS, and harvested by gentle scraping at 4C. Cells were
pelleted by centrifugation, washed with PBS, and re-pelleted. For MS analysis, cells were lysed in 10 volumes of lysis buffer (6 M
guanidine-HCl, 50 mM Tris, pH 8.5), and the lysate was immediately snap frozen using liquid nitrogen. For each single-shot MS repli-
cate, 75 million HeLa cells corresponded to 15 mg of total protein material. For each pre-fractionated MS replicate, 150 million
HeLa cells corresponded to30mgof total proteinmaterial. After thawing, cell lysateswere sonicated, and supplementedwith 5mM
TCEP and 10 mM chloroacetamide (CAA). The reduced and alkylated proteins were subsequently digested using Lysyl Endopepti-
dase (Lys-C, 1:100 w/w; Wako Chemicals), and with modified sequencing grade trypsin (1:100 w/w; Sigma Aldrich) after a threefold
dilution in 50 mM ammonium bicarbonate. Protease digestion was terminated by addition of trifluoroacetic acid (TFA) to a final con-
centration of 0.5% (v/v). Precipitates were removed by centrifugation, before peptides were purified using reversed-phase Sep-Pak
C18 cartridges (Waters). For WB analysis, cells were lysed in 10 volumes of WB lysis buffer (2% SDS, 150 mM NaCl, 50 mM Tris,
pH 8.5), and the lysates were immediately heated to 99C and shaken at 1,400 RPM for 30 minutes. Temperature-homogenized ly-
sates were equalized for protein concentration using Pierce BCA Protein Assay Kit (Thermo) according to themanufacturer’s instruc-
tions, and supplemented with ½ volume of 4 3 NuPAGE LDS Sample Buffer (Thermo).
Purification of GST-tagged Af1521 macrodomain
To purify ADP-ribosylated peptides, we utilized a GST-tagged Af1521 macrodomain, which can be readily produced in-house using
bacteria (Martello et al., 2016). Competent BL21(DE3) bacteria were used for expression of GST-tagged Af1521. In brief, the plasmid
was added to BL21(DE3) on ice, and incubated for 30 min. Bacteria were heat shocked at 42C for 45 s, incubated on ice, prior to
overnight incubation on ampicillin plates. A single colony was inoculated in LBmedia and grown overnight at 37C. The starter culture
was diluted, and grown to an OD600 of 0.55-0.65. Protein expression was induced by addition of IPTG, for 6 h at 30C. Bacteria were
pelleted by centrifugation, washed twice with PBS, and pellets were frozen at 80C until further processing. Bacterial pellets were
lysed using BugBuster Protein Extraction Reagent (Merck) according to the manufacturer’s instructions. GST-tagged Af1521 was
subsequently purified from the bacterial lysate using glutathione Sepharose 4B (Sigma Aldrich), by incubating the beads in the lysate
for 4 h at 4C. Beads were subsequently washed five times with PBS, and then stored until use at 4C in PBS supplemented with
10 mM sodium azide.
Enrichment of ADP-ribosylated peptides
To allow identification of ADP-ribosylation on peptides, ADP-ribosylation has to be reduced to monomers using the PARG enzyme,
and subsequently purified to a high degree using the Af1521 macrodomain and a considerable number of washing steps. Peptides
purified from digested HeLa lysates were eluted off the Sep-Pak cartridges using acetonitrile (ACN) in 0.1% TFA, and dried by vac-
uum centrifugation at 60C. Peptides were dissolved in Milli-Q water (MQ), and passed through 0.45 mm filters prior to concentration
determination by UV spectroscopy. Peptide amount at this stage was approximately 1/4th of the initial total protein amount. Samples
were subsequently buffered to achieve final concentrations of 50 mM TRIS pH 8.0, 1 mM MgCl2, 250 mM DTT, and 50 mM NaCl.
ADPr-polymer complexity was reduced by incubation with recombinant PARG (a kind gift from Prof. Dr. Michael O. Hottiger) at a
concentration of 1:10,000 (w/w, PARG-to-substrate), overnight at 20C. ADPr-modified peptides were subsequently purified by
addition of Sepharose beads with GST-tagged Af1521 macrodomain, and incubation for 3 h at 4C. The beads were washed four
times in ice-cold Wash Buffer (50 mM TRIS pH 8.0, 1 mM MgCl2, 250 mM DTT, 50 mM NaCl), two times in ice-cold PBS, and two
times in ice-cold MQ. ADP-ribosylated peptides were eluted off the beads over two rounds using two bead volumes ice-cold
0.15% TFA.
Enrichment of phosphorylated peptides
To evaluate the phosphoproteome, we used a similar experimental setup as for ADP-ribosylation, and used an established high-
efficiency method for purification of phosphopeptides. Quadruplicate HeLa cultures with 50 million cells were prepared, and
treated, lysed, and digested similarly to the HeLa cells prepared for ADP-ribosylation analysis. Trypsin-digested peptides were eluted
off Sep-Pak using acetonitrile (ACN) in 0.1% TFA, and all samples were brought to concentrations of 80% ACN and 5% TFA in a final
volume of 8 ml. Each sample (3 mg of peptides) was incubated with 1.5 mg of TiO2 beads (GL Sciences) for 30 min at room temper-
ature, followed by a second incubation of the unbound fractionwith another 1.5mg of TiO2 beads. Beadswerewashedwith ACN/TFA
on C8 StageTips, prior to elution with NH4OH (Bekker-Jensen et al., 2017).
Fractionation of peptides by StageTip
In order to achieve a considerable depth of sequencing, we used high-pH reversed-phase pre-fractionation to distribute the final
purified peptides across multiple fractions, with each of these fractions being considerably less complex than a single-shot sample.
One third of all ADP-ribosylation samples were acidified by addition of TFA to 1% final volume, and subsequently peptides wereCell Reports 24, 2493–2505.e1–e4, August 28, 2018 e2
purified and desalted using reversed-phase C18 StageTips (Rappsilber et al., 2003). Two thirds of all ADP-ribosylation samples were
supplemented with ammonium hydroxide to a final concentration of 20 mM, and peptides were purified, desalted, and fractionated
on-StageTip (Hendriks et al., 2017). ADP-ribosylation samples were eluted as six fractions using 2% (F1), 4% (F2), 7% (F3), 10% (F4),
15% (F5), and 25% (F6) of ACN in 20 mM ammonium hydroxide. Flow-through from the initial loading of the samples at high-pH was
acidified and processed on separate StageTips at low-pH, resulting in a seventh fraction (F0). Phosphorylation samples were eluted
as six fractions using 2% (F1), 4% (F2), 7% (F3), 10% (F4), 13% (F5), and 25% (F6) of ACN in 20mMammonium hydroxide. All peptide
elutions were vacuum-dried completely, and dissolved in a small volume of 0.1% formic acid.
Mass spectrometric analysis
We operated our chromatography equipment and mass spectrometers according to optimized protocols and methodology in order
to ensure amaximum degree of sensitivity. All ADP-ribosylation MS experiments were performed using a nanoscale EASY-nLC 1200
system (Thermo) connected to a Fusion LumosOrbitrapmass spectrometer (Thermo), whereas the phosphorylationMS experiments
were performed using a Q Exactive HF-X, both equipped with a nano-electrospray source (Thermo). All samples were analyzed on
15-cm long analytical columns, with an internal diameter of 75 mm, and packed in-house using ReproSil-Pur 120 C18-AQ 1.9 mm
beads (Dr. Maisch). Reversed-phase liquid chromatography was performed using an EASY-nLC 1200 system (Thermo). The analyt-
ical column was heated to 40C, and elution of peptides from the column was achieved by application of gradients with Buffer A
(0.1% formic acid) and increasing amounts of Buffer B (80% ACN in 0.1% formic acid). For single shot ADP-ribosylation samples,
the primary gradient ranged from 4% buffer B to 40% buffer B over 90 minutes, followed by an increase to 55% buffer B to ensure
elution of all peptides, followed by a washing block of 20 minutes. For fractionated ADP-ribosylation samples, the gradient ranged
from 3% buffer B to 40% buffer B over 62 minutes, followed by a washing block of 18 minutes. For fractionated phosphorylation
samples, the gradient ranged from 5%buffer B to 50% buffer B over 82minutes, followed by a washing block of 18 minutes. Electro-
spray ionization (ESI) was achieved using a Nanospray Flex Ion Source (Thermo). Spray voltagewas set to 2 kV, capillary temperature
to 275C, and RF level to 30% for all ADP-ribosylation samples, and 40% for phosphorylation samples. For ADP-ribosylation
samples, full scans were performed at a resolution of 60,000, with a scan range of 300 to 1,750 m/z, a maximum injection time of
60 ms, and an automatic gain control (AGC) target of 600,000 charges. Precursors were isolated with a width of 1.3 m/z, with an
AGC target of 200,000 charges, and precursor fragmentation was accomplished using electron transfer dissociation (ETD) using cali-
brated charge-dependent ETD parameters. Calibration of ETDwas essentially performed as described previously (Rose et al., 2015).
The ion trap and the Orbitrap were calibrated and evaluated in negative mode. For ETD, Reagent Transmission, IC Transmission, and
Reagent Ion Source were all evaluated on a weekly basis. The internal calibration stored in the instrument resulted in activation times
of 110.80 ms for z = 2 precursors, 49.24ms for z = 3 precursors, 27.70ms for z = 4 precursors, and 17.73ms for z = 5 precursors. This
equates to an ETD Time Constant (t) of 2.46. Only precursors with charge state 3-5 were considered, and prioritized from charge 3
(highest) to charge 5 (lowest), using the decision tree algorithm. Selected precursors were excluded from repeated sequencing by
setting a dynamic exclusion of 72 s for single shot samples, and 48 s for fractionated samples. MS/MS spectra were acquired in
the Orbitrap, and settings included a loop count of 5, a maximum injection time of 120 ms and a resolution of 60,000. For phosphor-
ylation samples, full scans were performed at a resolution of 60,000, with a scan range of 300 to 1,500m/z, a maximum injection time
of 60 ms, and an automatic gain control (AGC) target of 3e6 charges. Precursors were isolated with a width of 1.3m/z, with an AGC
target of 2e5 charges, and precursor fragmentation was accomplished using higher energy collision dissociation (HCD). Only pre-
cursors with charge state 2-5 were considered. Selected precursors were excluded from repeated sequencing by setting a dynamic
exclusion of 90 s. MS/MS spectra were acquired in the Orbitrap, and settings included a loop count of 9, a maximum injection time of
90 ms and a resolution of 45,000.
Data analysis
Analysis of the mass spectrometry raw data was performed using the MaxQuant software, which is freely available, routinely used in
the field, and one of the best solutions for studying PTMs. An overview detailing which RAW files correspond to which experimental
conditions is available (Table S1). For the ADP-ribosylation main search, all corresponding RAW files were analyzed using the freely
available MaxQuant software (version 1.5.3.30). Default MaxQuant settings were used, with exceptions outlined below. For gener-
ation of the theoretical spectral library, the HUMAN.fasta database was extracted from UniProt on the 23rd of January, 2018.
Cysteine carbamidomethylation, N-terminal acetylation, methionine oxidation, and ADP-ribosylation on a wide range of amino
acid residues (C, D, E, H, K, R, S, T, and Y) were included as variable modifications. Amaximum allowance of 5 variable modifications
per peptide was used. Label-free quantification (LFQ) was enabled. Second peptide search was enabled (default), and matching
between runs was enabled with a match time window of 1 minute and an alignment time window of 20 minutes. Data was filtered
by posterior error probability to achieve a false discovery rate of < 1% (default), at the peptide-spectrum match, the protein assign-
ment, and the site-specific levels. For the ADP-ribosylation unrestricted search, only single-shot RAW files were analyzed with
MaxQuant to minimize computational processing time. All other search parameters were the same as for the main search, with
exceptions outlined below. For the unrestricted search, ADP-ribosylation was allowed as a variable modification on all 20 naturally
occurring amino acids, no other variable modifications were considered, the maximum number of variable modifications per peptide
was set to 1, and themaximumpeptidemasswas set to 2,500. For the phosphorylationmain search, up to 8missed tryptic cleavages
were allowed, and a maximum peptide mass of 7,000 Da was set. Protein N-terminal acetylation, methionine oxidation, ande3 Cell Reports 24, 2493–2505.e1–e4, August 28, 2018
phosphorylation of serine, threonine, and tyrosine residues were included as potential variable modifications. A maximum allowance
of 4 variable modifications per peptide was used. Second peptide search was enabled (default), and matching between runs was
enabled with a match time window of 1 minute and an alignment time window of 20 minutes. Modified peptides were filtered
to have a delta score of at least 20. Data was additionally filtered by posterior error probability to achieve a false discovery rate
of < 1% (default), at the peptide-spectrum match, the protein assignment, and the site-specific levels.
Validation of ADPr on CHTY residues
We performed manual verification for three representative MS/MS spectra corresponding to ADP-ribosylation targeting cysteine,
histidine, threonine, or tyrosine residues, because modification of these residues has not previously been demonstrated using
MS/MS in combination with ETD fragmentation. The MaxQuant Viewer (integrated in MaxQuant 1.5.3.30) was used to export auto-
matically annotated ETDMS/MS spectra corresponding to peptides ADP-ribosylated on C, H, T, or Y residues, which were manually
verified for the presence of mass fragments unequivocally demonstrating correct localization. The annotated spectra are available as
Supplemental Data (Data S1).
Western blot analysis
We utilized western blot analysis to investigate the phosphorylation state of specific proteins of interest. Total HeLa cell lysates were
size-separated on 4%–12% Bis-Tris gels using MOPS running buffer, and transferred to PVDF membranes (Millipore). Total protein
loading was ensured by Ponceau-S staining. Membranes were blocked using 5% BSA solution in PBS supplemented with 0.1%
Tween-20 (PBST) for 1 h. Subsequently, membranes were incubated with primary antibodies overnight at 4C. Membranes were
washed three times with PBST, and incubated with Goat-anti-rabbit HRP conjugated secondary antibody (Jackson Immunore-
search, 111-036-045) at a concentration of 1:2500 for 1 h at room temperature. Membraneswere washed three timeswith PBST prior
to detection using Novex ECL Chemiluminescent Substrate Reagent Kit (Invitrogen). The following primary antibodies were used in
this study: phospho-Aurora A (Thr288)/Aurora B (Thr232)/Aurora C (Thr198) rabbit mAb, phospho-Histone H3 (Ser10) rabbit mAb, and
phospho-TACC3 (Ser558) rabbit mAb (all from Cell Signaling Technology), all diluted 1:1,000 in 5% BSA.
QUANTIFICATION AND STATISTICAL ANALYSIS
Details regarding the statistical analysis can be found in the respective figure legends. Statistical handling of the data was primarily
performed using the freely available Perseus software (Tyanova et al., 2016), and includes log2 transformations, n = 4 filtering,
imputation (down shift 1.8, width 0.3), scatterplot analysis, principle component analysis, Z-scoring, unsupervised hierarchical clus-
tering, and enrichment analysis through FDR-controlled Fisher Exact testing. Protein annotations used for term enrichment analysis,
including Gene Ontology, keywords, and Pfam, were concomitantly downloaded from UniProt with the HUMAN.fasta file used for
searching the RAW data. The iceLogo software (version 2.1) was used for sequence motif analysis (Colaert et al., 2009). The online
Kinase-Substrate Enrichment Application (KSEA) was used for matching kinase motifs to all serines in ADPr-modified proteins
(Casado et al., 2013), with kinase motifs extracted from PhosphoSitePlus (Hornbeck et al., 2012) and Networkin (Linding et al.,
2007). The online STRING database (version 10.5) was used for generation of protein interaction networks (Szklarczyk
et al., 2015), and Cytoscape (version 3.6.0) was used for manual annotation and visualization of the STRING networks (Shannon
et al., 2003).
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the ADP-ribosylation data and the phosphorylation data reported in this paper are ProteomeXchange
Consortium PRIDE: PXD009208 and PXD009931, respectively (Vizcaı´no et al., 2013).Cell Reports 24, 2493–2505.e1–e4, August 28, 2018 e4
